|
|
This gene has the annotation "riboflavin kinase/FMN adenylyltransferase".
The target was selected as part of Igor's sets.
Available sections:
| Experiment | Result | User | Experiment Date |
|---|---|---|---|
| Selected | Done | jmc | 2001-08-24 |
| Cloned | Done | abwaight | 2001-10-01 |
| Expression tested | Done | abwaight | 2001-10-01 |
| Solubility tested | S | abwaight | 2001-10-01 |
| Purified | Done | abwaight | 2001-10-01 |
| Crystallized | Done | abwaight | 2001-10-01 |
| Diffraction quality crystals | Done | abwaight | 2001-10-01 |
| Native diffraction data | Done | abwaight | 2001-10-01 |
| Phasing diffraction data | Done | abwaight | 2001-10-01 |
| Traceable map | Done | abwaight | 2001-10-01 |
| Crystal structure | Done | dhshin | 2006-08-16 |
| In PDB | 1MRZ 1S4M 1T6X 1T6Y 1T6Z 2I1L | dhshin | 2006-08-16 |
| Biochemical function | Done | dhshin | 2002-10-22 |
| MP gene | log10(PSIBLAST E) | % identical | % coverage (of MP gene) |
|---|---|---|---|
| MP673 / MPN158 | -47.00 | 27.82 | 96.93 |
ATGGTTGTCAGCATCGGAGTTTTCGATGGAGTTCACATCGGGCATCAGAAGGTCTTGAGGACCATGAAGGAAATAGCATT TTTCAGGAAGGACGATAGCCTTATCTACACCATATCTTATCCCCCCGAATATTTCTTACCGGATTTTCCCGGTCTTCTCA TGACGGTAGAAAGCAGGGTGGAGATGCTTTCTCGTTACGCCAGAACCGTTGTTCTGGATTTTTTCAGAATAAAAGATCTC ACCCCAGAAGGGTTCGTCGAGAGGTATCTATCTGGAGTATCGGCTGTTGTTGTTGGAAGGGATTTCAGATTTGGCAAGAA CGCGAGCGGAAACGCGTCTTTTCTCAGAAAGAAAGGTGTGGAAGTCTATGAAATTGAAGATGTCGTTGTTCAGGGAAAAA GAGTGAGCAGTTCTCTGATCAGAAACCTCGTTCAGGAGGGAAGAGTGGAGGAAATTCCTGCATATCTCGGCAGATATTTC GAAATCGAAGGAATCGTCCACAAAGATAGGGAATTTGGAAGAAAACTGGGATTTCCAACTGCCAACATCGATAGAGGAAA TGAAAAACTCGTAGATCTGAAAAGAGGAGTTTATCTGGTGAGAGTTCATCTGCCGGATGGAAAGAAAAAATTCGGTGTTA TGAACGTGGGTTTCAGGCCCACCGTGGGTGATGCGAGAAACGTGAAGTACGAGGTGTACATCCTGGATTTCGAAGGGGAT CTTTACGGGCAGAGACTGAAACTGGAAGTATTGAAATTCATGAGGGATGAGAAGAAATTTGATTCAATCGAGGAGCTGAA GGCTGCTATTGACCAGGATGTAAAGAGCGCCAGAAACATGATAGATGATATAATCAATTCGAAGTTCGAAAAAGAGGGGT GA
(294 codons) fields: [triplet] [frequency: per thousand] ([number]) UUU27.2( 8) UCU17.0( 5) UAU23.8( 7) UGU0.0( 0) UUC40.8( 12) UCC0.0( 0) UAC17.0( 5) UGC0.0( 0) UUA3.4( 1) UCA3.4( 1) UAA0.0( 0) UGA3.4( 1) UUG6.8( 2) UCG6.8( 2) UAG0.0( 0) UGG0.0( 0) CUU13.6( 4) CCU3.4( 1) CAU6.8( 2) CGU3.4( 1) CUC20.4( 6) CCC13.6( 4) CAC6.8( 2) CGC0.0( 0) CUA3.4( 1) CCA6.8( 2) CAA0.0( 0) CGA0.0( 0) CUG34.0( 10) CCG6.8( 2) CAG17.0( 5) CGG0.0( 0) AUU10.2( 3) ACU3.4( 1) AAU6.8( 2) AGU3.4( 1) AUC34.0( 10) ACC17.0( 5) AAC23.8( 7) AGC20.4( 6) AUA17.0( 5) ACA0.0( 0) AAA44.2( 13) AGA51.0( 15) AUG23.8( 7) ACG3.4( 1) AAG37.4( 11) AGG27.2( 8) GUU47.6( 14) GCU10.2( 3) GAU64.6( 19) GGU17.0( 5) GUC20.4( 6) GCC10.2( 3) GAC6.8( 2) GGC6.8( 2) GUA17.0( 5) GCA6.8( 2) GAA51.0( 15) GGA44.2( 13) GUG30.6( 9) GCG10.2( 3) GAG30.6( 9) GGG17.0( 5)
Details (problem DNA region is in upper case, with the key on the line below):
Key:
atggttgtcagcatcggagttttcgatggagttcacatcgggcatcagaaggtcttgagg
accatgaaggaaatagcatttttcaggaaggacgatagccttatctacaccatatcttat
ccccccgaatatttcttaccggattttcccggtcttctcatgacggtagaaagcagggtg
gagatgctttctcgttacgccagaaccgttgttctggattttttcagaataaaAGATCTc
4
accccagaagggttcgtcgagaggtatctatctggagtatcggctgttgttgttggaagg
gatttcagatttggcaagaacgcgagcggaaacgcgtcttttctcagaaagaaaggtgtg
gaagtctatgaaattgaagatgtcgttgttcagggaaaaagagtgagcagttctcTGATC
3
Agaaacctcgttcaggagggaagagtggaggaaattcctgcatatctcggcagatatttc
gaaatcgaaggaatcgtccacaaagatagggaatttggaagaaaactgggatttccaact
gccaacatcgatagaggaaatgaaaaactcgtAGATCTgaaaagaggagtttatctggtg
4
agagttcatctgccggatggaaagaaaaaattcggtgttatgaacgtgggtttcaggccc
accgtgggtgatgcgagaaacgtgaagtacgaggtgtacatcctggatttcgaaggggat
ctttacgggcagagactgaaactggaagtattgaaattcatgagggatgagaagaaattt
gattcaatcgaggagctgaaggctgctattgaccaggatgtaaagagcgccagaaacatg
atagatgatataatcaattcgaagttcgaaaaagaggggtga
Note: These were generated using Hisao's algorithm, and do not take into account possible mispriming, self-complementarity, or requirements for mutations anywhere in the sequences. The -R1 primers are for the N-terminal end, and begin with an NdeI restriction site (CATATG). The -R2 primers are for the C-terminal end, and begin with a BamHI site (GGATCC) if the target has no other BamHI sites. If the target does have a BamHI site, the -R2 primer wil begin with a BglII site (AGATCT), unless the target has no BglII sites. If the target has both sites, the design program gives up and doesn't prepend a restriction site to the -R2 primer!
Predicted Tm was obtained using the Tm determination tool at the Virtual Genome Center.
| Primer ID | Predicted Tm | sequence |
|---|---|---|
| 1099B-R1 | 60.30 | CATATGGTTGTCAGCATCGGAGT |
| 1099B-R2 | 62.40 | GGATCCTTATCACCCCTTTTCGAACTTCG |
| 1099B-R3 | 61.70 | GGATCCTTACCCCTCTTTTTCGAACTTCG |
| 1099B-R10 | 64.00 | GGCGGTGGTGGCGGCATGGTTGTCAGCATCGGAGTTTT |
| 1099B-R11 | 63.30 | GTTCTTCTCCTTTGCGCCCCTACCCCTCTTTTTCGAACTTCGA |
Note: This was generated using the standard codon usage table; UGA codons in MP/MP genes will show up as terminators ("*")
atggttgtcagcatcggagttttcgatggagttcacatcgggcatcagaaggtcttgagg M V V S I G V F D G V H I G H Q K V L R accatgaaggaaatagcatttttcaggaaggacgatagccttatctacaccatatcttat T M K E I A F F R K D D S L I Y T I S Y ccccccgaatatttcttaccggattttcccggtcttctcatgacggtagaaagcagggtg P P E Y F L P D F P G L L M T V E S R V gagatgctttctcgttacgccagaaccgttgttctggattttttcagaataaaagatctc E M L S R Y A R T V V L D F F R I K D L accccagaagggttcgtcgagaggtatctatctggagtatcggctgttgttgttggaagg T P E G F V E R Y L S G V S A V V V G R gatttcagatttggcaagaacgcgagcggaaacgcgtcttttctcagaaagaaaggtgtg D F R F G K N A S G N A S F L R K K G V gaagtctatgaaattgaagatgtcgttgttcagggaaaaagagtgagcagttctctgatc E V Y E I E D V V V Q G K R V S S S L I agaaacctcgttcaggagggaagagtggaggaaattcctgcatatctcggcagatatttc R N L V Q E G R V E E I P A Y L G R Y F gaaatcgaaggaatcgtccacaaagatagggaatttggaagaaaactgggatttccaact E I E G I V H K D R E F G R K L G F P T gccaacatcgatagaggaaatgaaaaactcgtagatctgaaaagaggagtttatctggtg A N I D R G N E K L V D L K R G V Y L V agagttcatctgccggatggaaagaaaaaattcggtgttatgaacgtgggtttcaggccc R V H L P D G K K K F G V M N V G F R P accgtgggtgatgcgagaaacgtgaagtacgaggtgtacatcctggatttcgaaggggat T V G D A R N V K Y E V Y I L D F E G D ctttacgggcagagactgaaactggaagtattgaaattcatgagggatgagaagaaattt L Y G Q R L K L E V L K F M R D E K K F gattcaatcgaggagctgaaggctgctattgaccaggatgtaaagagcgccagaaacatg D S I E E L K A A I D Q D V K S A R N M atagatgatataatcaattcgaagttcgaaaaagaggggtga I D D I I N S K F E K E G *
MVVSIGVFDGVHIGHQKVLRTMKEIAFFRKDDSLIYTISYPPEYFLPDFPGLLMTVESRVEMLSRYARTVVLDFFRIKDL TPEGFVERYLSGVSAVVVGRDFRFGKNASGNASFLRKKGVEVYEIEDVVVQGKRVSSSLIRNLVQEGRVEEIPAYLGRYF EIEGIVHKDREFGRKLGFPTANIDRGNEKLVDLKRGVYLVRVHLPDGKKKFGVMNVGFRPTVGDARNVKYEVYILDFEGD LYGQRLKLEVLKFMRDEKKFDSIEELKAAIDQDVKSARNMIDDIINSKFEKEG
This information was obtained using the Protein Parameters tool on the ExPASy Molecular Biology Server.
Number of amino acids: 293
Molecular weight: 33613.8
Theoretical pI: 8.77
Amino acid composition:
Ala (A) 11 3.8%
Arg (R) 24 8.2%
Asn (N) 9 3.1%
Asp (D) 21 7.2%
Cys (C) 0 0.0%
Gln (Q) 5 1.7%
Glu (E) 24 8.2%
Gly (G) 25 8.5%
His (H) 4 1.4%
Ile (I) 18 6.1%
Leu (L) 24 8.2%
Lys (K) 24 8.2%
Met (M) 7 2.4%
Phe (F) 20 6.8%
Pro (P) 9 3.1%
Ser (S) 15 5.1%
Thr (T) 7 2.4%
Trp (W) 0 0.0%
Tyr (Y) 12 4.1%
Val (V) 34 11.6%
Asx (B) 0 0.0%
Glx (Z) 0 0.0%
Xaa (X) 0 0.0%
Total number of negatively charged residues (Asp + Glu): 45
Total number of positively charged residues (Arg + Lys): 48
Atomic composition:
Carbon C 1523
Hydrogen H 2409
Nitrogen N 411
Oxygen O 432
Sulfur S 7
Formula: C1523H2409N411O432S7
Total number of atoms: 4782
Extinction coefficients:
Conditions: 6.0 M guanidium hydrochloride
0.02 M phosphate buffer
pH 6.5
Extinction coefficients are in units of M-1 cm-1 .
276 278 279 280 282
nm nm nm nm nm
Ext. coefficient 17400 16800 16140 15360 14400
Abs 0.1% (=1 g/l) 0.518 0.500 0.480 0.457 0.428
Estimated half-life:
The N-terminal of the sequence considered is M (Met).
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Instability index:
The instability index (II) is computed to be 30.79
This classifies the protein as stable.
Aliphatic index: 93.31
Grand average of hydropathicity (GRAVY): -0.252